Unlocking the 'Click': A Deep Dive into the Pathophysiology of Mitral Valve Prolapse

Mitral Valve Prolapse (MVP) is a valvular heart condition defined by the billowing of one or both mitral valve leaflets into the left atrium during ventricular systole. The fundamental pathophysiological mechanism is myxomatous degeneration, a progressive disorder of connective tissue. This process involves the excessive deposition of glycosaminoglycans in the valve's spongiosa layer and the fragmentation of structural collagen fibers. These changes render the leaflets thick, floppy, and redundant, and can similarly weaken the supporting chordae tendineae. MVP can be a primary, inherited condition or occur secondarily as a feature of systemic disorders like Marfan syndrome. The clinical manifestations of MVP are a direct result of these structural changes. The classic mid-systolic click heard on auscultation is the sound of the redundant leaflet apparatus snapping taut as it prolapses. If the leaflets fail to seal properly, it leads to mitral regurgitation (MR), heard as a late systolic murmur. Chronic MR imposes a significant volume overload on the left side of the heart, causing dilation of the left atrium and ventricle. This can ultimately lead to serious complications, including atrial fibrillation, congestive heart failure, and, more rarely, acute chordal rupture, infective endocarditis, or dangerous arrhythmias.

1. Introduction: The Mitral Valve and Defining Prolapse

The heart's four valves act as one-way doors, ensuring blood flows in a single, forward direction. The mitral valve, situated between the left atrium (LA) and the left ventricle (LV), plays a critical role. Composed of two leaflets (anterior and posterior), it opens during diastole to allow the LV to fill with oxygenated blood from the LA. During systole (ventricular contraction), it snaps shut, preventing blood from flowing backward into the LA.

Mitral Valve Prolapse (MVP) is a condition where one or both mitral valve leaflets do not close properly. Instead, they billow or bulge back into the left atrium during systole. Imagine a parachute that puffs upward against the wind instead of staying taut—this is an excellent analogy for the prolapsing leaflet. MVP is the most common valvular heart condition, often benign, but its underlying pathophysiology can lead to significant complications.

2. The Foundation of Failure: Myxomatous Degeneration

The central pathological process driving most cases of MVP is myxomatous degeneration. This is a disorder of connective tissue that weakens the structural integrity of the valve leaflets and their supporting structures. To understand this, we must first look at the normal leaflet histology, which consists of three layers:

1. Fibrosa: The dense, collagen-rich outer layer facing the aortic outflow, providing structural strength.
2. Spongiosa: The middle layer, rich in proteoglycans and glycosaminoglycans (GAGs), acting as a shock absorber.
3. Atrialis/Ventricularis: The inner layer containing elastin fibers.

In myxomatous degeneration, this organized structure breaks down:

• Collagen Disruption: The normally dense and organized collagen fibers within the fibrosa layer become fragmented, disorganized, and thinner.
• Spongiosa Proliferation: The spongiosa layer expands dramatically due to the excessive deposition of GAGs (acid mucopolysaccharides). This accumulation of gelatinous material is the hallmark of "myxomatous" change.

This process transforms the leaflets from firm, strong structures into thickened, redundant, and floppy ones. The chordae tendineae—the fibrous "heart strings" that tether the leaflets to the papillary muscles in the ventricle—are also affected. They can become elongated, thinned, and weakened, increasing their risk of rupture.

3. Etiology: Why Does Myxomatous Degeneration Occur?

MVP is broadly categorized by its cause:

• Primary (Nonsyndromic) MVP: This is the most common form, often referred to as idiopathic. There is a strong genetic predisposition, with an autosomal dominant inheritance pattern observed in many families. This means an affected person has a 50% chance of passing the responsible gene to their child. Genes implicated, such as FLNA (filamin A), are involved in cytoskeletal structure, highlighting the systemic nature of this connective tissue abnormality.

• Secondary (Syndromic) MVP: In this case, MVP is a manifestation of a systemic connective tissue disorder. The underlying genetic defect affects structural proteins throughout the body, including the mitral valve. Real-world examples include:

Marfan Syndrome: Caused by a mutation in the FBN1 gene, which codes for fibrillin-1, a crucial component of microfibrils that provide strength and elasticity to connective tissue. The resulting weak tissue makes valve prolapse and aortic root dilation common. Ehlers-Danlos Syndrome (EDS): A group of disorders characterized by defects in collagen synthesis and structure. The hypermobile joints and fragile skin seen in EDS are external signs of the same underlying weakness that can cause MVP. * Osteogenesis Imperfecta: A disorder of Type I collagen synthesis, leading to brittle bones and, in some cases, MVP.

4. Hemodynamic Consequences and Clinical Manifestations

The pathological changes of myxomatous degeneration lead directly to the clinical signs and potential complications of MVP.

Auscultatory Findings:

• Mid-Systolic Click: This is the classic sound of MVP. During systole, as LV pressure rises, the redundant, floppy leaflet is forced back into the LA. The "click" is the high-pitched sound produced when the elongated chordae tendineae are suddenly snapped taut, halting the leaflet's backward motion. The timing of the click can be altered by bedside maneuvers. Standing or a Valsalva maneuver decreases LV volume, causing the prolapse to occur earlier in systole (earlier click). Squatting increases LV volume, delaying the prolapse and the click.
• Late Systolic Murmur: If the prolapse is severe enough that the leaflets fail to coapt (meet and seal), a gap is created. Blood then regurgitates back into the LA. This turbulent backflow produces a high-pitched murmur that is heard after the click and continues to the end of systole.

Progression to Mitral Regurgitation (MR): The most significant complication of MVP is the development of chronic, progressive mitral regurgitation (MR). The constant backflow of blood imposes a volume overload on the heart:

1. Left Atrial Dilation: The LA must accommodate both the normal blood flow from the lungs and the regurgitant volume from the LV. Over time, it stretches and dilates. This stretching can disrupt the heart's electrical pathways, leading to a high risk of atrial fibrillation.
2. Left Ventricular Dilation and Hypertrophy: The LV must pump a larger total volume (forward stroke volume + regurgitant volume) to maintain adequate cardiac output. This leads to eccentric hypertrophy, where the ventricle dilates and its walls thicken to handle the increased workload. Initially compensatory, this process eventually leads to ventricular dysfunction and congestive heart failure.

Acute Complications:

• Chordal Rupture: A weakened, myxomatous chorda tendinea can spontaneously rupture. This causes a portion of the leaflet to become flail, leading to sudden, severe MR. This is a medical emergency presenting as acute pulmonary edema and cardiogenic shock.
• Infective Endocarditis: The damaged, irregular surface of the myxomatous valve is a prime location for bacteria to adhere and form vegetations, increasing the risk of this serious infection.
• Arrhythmias and Sudden Cardiac Death: While very rare, MVP is associated with an increased risk of both atrial and ventricular arrhythmias. In a small subset of patients with specific high-risk features (e.g., flail leaflet, severe MR, specific ECG changes), there is a risk of sudden cardiac death.

Browse public study notes